Alpha4beta2-nicotinic Receptor Binding with 5-IA in Alzheimer's Disease: Methods of Scan Analysis

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2007 Oct 26

PMID 17960479

Citations 6

Authors

Emma Terriere

Mike Sharman

Claire Donaghey

Lucie Herrmann

Jane Lonie

Marion Strachan

Nadine Dougall

Jonathan Best

Klaus P Ebmeier

Sally Pimlott

Jim Patterson

David Wyper

Affiliations

Soon will be listed here.

Abstract

Five patients with Alzheimer's disease and five healthy volunteers were examined by SPECT with the nicotinic receptor ligand 123I-5-IA-85380. Patients were scanned before and after 6 weeks of treatment with donepezil. Quantification by regions of interest was reliable and the optimal normalisation procedure used cerebellar ratios. We found relative reductions in 5-IA binding capacity in patients in thalamus, frontal and central regions of interest of approximately one standard deviation unit (Cohen's d = 1). Reductions in binding after treatment with the acetylcholinesterase inhibitor donepezil of the same magnitude occurred in the brain stem. The study was clearly too small to confirm group differences, but it suggests that 5-IA can be used to examine both group differences and treatment effects in patients with Alzheimer's disease.

Citing Articles

Evaluation of the Relationship Between Cognitive Impairment, Glycometabolism, and Nicotinic Acetylcholine Receptor Deficits in a Mouse Model of Alzheimer's Disease.

Matsuura Y, Ueda M, Higaki Y, Sano K, Saji H, Enomoto S Mol Imaging Biol. 2018; 21(3):519-528.

PMID: 30047036 DOI: 10.1007/s11307-018-1253-4.

Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Hirao K, Pontone G, Smith G Neurosci Biobehav Rev. 2014; 49:157-70.

PMID: 25446948 PMC: 4806385. DOI: 10.1016/j.neubiorev.2014.11.010.

Synthesis and evaluation of 3-¹²³I-iodo-5-[2-(S)-3-pyrrolinylmethoxy]-pyridine (niodene) as a potential nicotinic α4β2 receptor imaging agent.

Pandey S, Pan S, Kant R, Kuruvilla S, Pan M, Mukherjee J Bioorg Med Chem Lett. 2012; 22(24):7610-4.

PMID: 23116890 PMC: 3508149. DOI: 10.1016/j.bmcl.2012.10.012.

Quantitative Molecular Imaging of Neuronal Nicotinic Acetylcholine Receptors in the Human Brain with A-85380 Radiotracers.

Lotfipour S, Mandelkern M, Brody A Curr Med Imaging Rev. 2012; 7(2):107-112.

PMID: 22773924 PMC: 3389797. DOI: 10.2174/157340511795445676.

Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography.

Kendziorra K, Wolf H, Meyer P, Barthel H, Hesse S, Becker G Eur J Nucl Med Mol Imaging. 2010; 38(3):515-25.

PMID: 21069319 DOI: 10.1007/s00259-010-1644-5.

References

Mathuranath P, Nestor P, Berrios G, Rakowicz W, Hodges J . A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology. 2000; 55(11):1613-20. DOI: 10.1212/01.wnl.0000434309.85312.19. View

. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry. 1994; 57(4):416-8. PMC: 1072868. DOI: 10.1136/jnnp.57.4.416. View

Harrison J, Buxton P, Husain M, Wise R . Short test of semantic and phonological fluency: normal performance, validity and test-retest reliability. Br J Clin Psychol. 2000; 39(2):181-91. DOI: 10.1348/014466500163202. View

Fujita M, Seibyl J, Vaupel D, Tamagnan G, Early M, Zoghbi S . Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imaging. 2002; 29(2):183-90. DOI: 10.1007/s00259-001-0695-z. View

Elser H, Henze M, Spierer F, Georgi P . [Semiquantitative 99mTc-HMPAO SPECT in dementia of the Alzheimer type: influence of the selection of reconstruction filter and reference region]. Nuklearmedizin. 1996; 35(6):243-50. View

Soonawala D, Amin T, Ebmeier K, Douglas Steele J, Dougall N, Best J . Statistical parametric mapping of (99m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake. Neuroimage. 2002; 17(3):1193-202. DOI: 10.1006/nimg.2002.1259. View

Nordberg A, Winblad B . Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett. 1986; 72(1):115-9. DOI: 10.1016/0304-3940(86)90629-4. View

Dougall N, Bruggink S, Ebmeier K . Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry. 2004; 12(6):554-70. DOI: 10.1176/appi.ajgp.12.6.554. View

Talbot P, Lloyd J, Snowden J, Neary D, Testa H . Choice of reference region in the quantification of single-photon emission tomography in primary degenerative dementia. Eur J Nucl Med. 1994; 21(6):503-8. DOI: 10.1007/BF00173036. View

10.

Yesavage J . Geriatric Depression Scale. Psychopharmacol Bull. 1988; 24(4):709-11. View

11.

Martin-Ruiz C, Court J, Molnar E, Lee M, Gotti C, Mamalaki A . Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem. 1999; 73(4):1635-40. DOI: 10.1046/j.1471-4159.1999.0731635.x. View

12.

Burghaus L, Schutz U, Krempel U, de Vos R, Jansen Steur E, Wevers A . Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res. 2000; 76(2):385-8. DOI: 10.1016/s0169-328x(00)00031-0. View

13.

ROSEN W, Terry R, Fuld P, Katzman R, Peck A . Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980; 7(5):486-8. DOI: 10.1002/ana.410070516. View

14.

Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J . Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci. 1999; 11(7):2551-65. DOI: 10.1046/j.1460-9568.1999.00676.x. View

15.

Mukhin A, Gundisch D, Horti A, Koren A, Tamagnan G, Kimes A . 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol. 2000; 57(3):642-9. DOI: 10.1124/mol.57.3.642. View

16.

Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B . Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord. 1995; 9(1):21-7. DOI: 10.1097/00002093-199505000-00006. View

17.

Pickut B, Dierckx R, Dobbeleir A, Audenaert K, Van Laere K, Vervaet A . Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type. Psychiatry Res. 1999; 90(2):103-12. DOI: 10.1016/s0925-4927(99)00004-9. View

18.

Baddeley A, Wilson B . When implicit learning fails: amnesia and the problem of error elimination. Neuropsychologia. 1994; 32(1):53-68. DOI: 10.1016/0028-3932(94)90068-x. View

19.

Mamede M, Ishizu K, Ueda M, Mukai T, Iida Y, Fukuyama H . Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT. J Nucl Med. 2004; 45(9):1458-70. View

20.

Martin-Ruiz C, COURT J, Lee M, Piggott M, Johnson M, Ballard C . Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol Scand Suppl. 2001; 176:34-41. DOI: 10.1034/j.1600-0404.2000.00305.x. View